Evidence map›Paper›PMID 23919219›Full record

ArticleWorld journal of gastrointestinal pharmacology and therapeutics2013

Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition.

Ian Leonard Phillip Beales, Abigail Hensley, Yoon Loke

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal pharmacology and therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 4 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Relation of Statin Use with Esophageal Cancer.Pharmaceuticals (Basel, Switzerland) · 2023
    Article
  6. Statins as Potential Therapeutics for Esophageal Cancer.Journal of gastrointestinal cancer · 2021
    Review
  7. Review
  8. Chemoprevention in Barrett's esophagus and esophageal adenocarcinoma.Therapeutic advances in gastroenterology · 2021
    Review
  9. Review
  10. Article
  11. Expression Rate andOpen access Macedonian journal of medical sciences · 2018
    Article
  12. Review
  13. Review
  14. Article
  15. Barrett's oesophagus: how should we manage it?Frontline gastroenterology · 2015
    Review
  16. Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma.World journal of gastrointestinal pathophysiology · 2014
    Review
  17. The role of obesity in oesophageal cancer development.Therapeutic advances in gastroenterology · 2014
    Review
  18. Review
  19. Article
  20. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Ian Leonard Phillip BealesIan Leonard Phillip Beales, Department of Gastroenterology, Norfolk and Norwich University Hospital, Norwich NR4 7UY, United Kingdom.
Abigail Hensley
Yoon Loke
University of East Anglia · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo examine the association between statin use and the development of esophageal cancer

methodsWe performed a systematic review and meta-analysis. Multiple databases (Pubmed, EMBASE, Cochrane Library, Web of Science, Wiley Interscience and Google Scholar) were systematically searched for studies reporting the association of statin use and the development of esophageal cancer. Literature searching and data abstraction were performed independently by two separate researchers. The quality of studies reviewed was evaluated using the Newcastle-Ottawa Quality assessment scale. Meta-analysis on the relationship between statin use and cancer incidence was performed. The effect of the combination of statin plus a cyclo-oxygenase inhibitor was also examined.

resultsEleven studies met eligibility criteria, 9 high and 2 medium quality. All were observational studies. Studies examining adenocarcinoma development in Barrett's esophagus included 317 cancers and 1999 controls, population-based studies examining all esophageal cancers included 371203 cancers and 6083150 controls. In the Barrett's population the use of statins (OR = 0.57; 95%CI: 0.43-0.75) and cyclo-oxygenase inhibitors (OR = 0.59; 95%CI: 0.45-0.77) were independently associated with a reduced incidence of adenocarcinoma. Combined use of a statin plus cyclo-oxygenase inhibitor was associated with an even lower adenocarcinoma incidence (OR = 0.26; 95%CI: 0.1-0.68). There was more heterogeneity in the population-based studies but pooled adjusted data showed that statin use was associated with a lower incidence of all combined esophageal cancers (OR = 0.81; 95%CI: 0.75-0.88).

conclusionStatin use in patients with Barrett's oesophagus is associated with a significantly lower incidence of adenocarcinoma. The chemopreventive actions of statins, especially combined with cyclo-oxygenase inhibitors deserve further exploration.

Indexed as

AspirinBarrett’s oesophagusCancer riskChemopreventionEsophageal carcinomaNon-steroidal anti-inflammatory drugsStatins

Identifiers

PMID23919219
PMCPMC3729870
OpenAlexW123024208

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.